← Back to Search

Other

Respirogen Micro-Oxygen for Hypoxic Ventilatory Response

Phase < 1
Waitlist Available
Led By Chris Bell, PhD
Research Sponsored by Christopher Bell
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new technology called Respirogen Micro-Oxygen (RMO) that delivers oxygen directly to the body through the rectum. The study focuses on healthy adults in low-oxygen environments to see how their bodies respond. This method could help people who have trouble breathing by providing oxygen without needing to inhale it.

Eligible Conditions
  • Hypoxic Ventilatory Response
  • Hypoxia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomized crossover, visits separated by a minimum 7 days and maxim 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and randomized crossover, visits separated by a minimum 7 days and maxim 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Increases Oxygen saturation (SpO2) with RMO

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Low Oxygen Visits with Respirogen Micro-OxygenExperimental Treatment1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
Group II: Low Oxygen Visits without Respirogen Micro-OxygenActive Control1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.

Find a Location

Who is running the clinical trial?

Christopher BellLead Sponsor
8 Previous Clinical Trials
234 Total Patients Enrolled
Respirogen Inc.UNKNOWN
Chris Bell, PhDPrincipal InvestigatorCSU
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top